| | | | | | | |
(millions) | Three Months Ended March 31, 2020 | |
| | 2020 Reported Valued at 2020 Management Rates | | Discontinued Operations and Related Allocation Changes | | 2020 Continuing Operations Valued at 2020 Management Rates | |
Net Sales | | | | | | | |
Global Industrial | | $1,444.0 | | $(0.4) | | $1,443.6 | |
Global Institutional | | 1,072.3 | | (0.2) | | 1,072.1 | |
Global Healthcare and Life Sciences | | 246.2 | | 0.3 | | 246.5 | |
Upstream Energy | | 562.7 | | (562.7) | | - | |
Other | | 277.8 | | (0.2) | | 277.6 | |
Subtotal at fixed currency | | 3,603.0 | | (563.2) | | 3,039.8 | |
Effect of foreign currency translation | | (21.6) | | 2.4 | | (19.2) | |
Total reported GAAP net sales | | $3,581.4 | | $(560.8) | | $3,020.6 | |
Operating Income | | | | | | | |
Global Industrial | | $226.9 | | $(20.3) | | $206.6 | |
Global Institutional | | 183.5 | | (1.1) | | 182.4 | |
Global Healthcare and Life Sciences | | 25.6 | | (2.7) | | 22.9 | |
Upstream Energy | | 39.0 | | (39.0) | | - | |
Other | | 25.3 | | (3.7) | | 21.6 | |
Corporate | | (100.2) | | 45.6 | | (54.6) | |
Subtotal at fixed currency | | 400.1 | | (21.2) | | 378.9 | |
Effect of foreign currency translation | | (2.9) | | 0.2 | | (2.7) | |
Total reported GAAP operating income | | $397.2 | | $(21.0) | | $376.2 | |
| | | | | | | |
| | Twelve Months Ended December 31, 2019 | |
| | 2019 Reported Valued at 2020 Management Rates | | Discontinued Operations and Related Allocation Changes | | 2019 Continuing Operations Valued at 2020 Management Rates | |
Net Sales | | | | | | | |
Global Industrial | | $5,996.4 | | $(1.8) | | $5,994.6 | |
Global Institutional | | 4,412.1 | | - | | 4,412.1 | |
Global Healthcare and Life Sciences | | 979.0 | | - | | 979.0 | |
Upstream Energy | | 2,352.9 | | (2,352.9) | | - | |
Other | | 1,211.7 | | - | | 1,211.7 | |
Subtotal at fixed currency | | 14,952.1 | | (2,354.7) | | 12,597.4 | |
Effect of foreign currency translation | | (45.8) | | 10.4 | | (35.4) | |
Total reported GAAP net sales | | $14,906.3 | | $(2,344.3) | | $12,562.0 | |
Operating Income | | | | | | | |
Global Industrial | | $980.6 | | $(77.9) | | $902.7 | |
Global Institutional | | 947.3 | | (7.5) | | 939.8 | |
Global Healthcare and Life Sciences | | 135.1 | | (10.6) | | 124.5 | |
Upstream Energy | | 187.9 | | (187.9) | | - | |
Other | | 180.6 | | (13.6) | | 167.0 | |
Corporate | | (407.9) | | 128.2 | | (279.7) | |
Subtotal at fixed currency | | 2,023.6 | | (169.3) | | 1,854.3 | |
Effect of foreign currency translation | | (9.8) | | 0.7 | | (9.1) | |
Total reported GAAP operating income | | $2,013.8 | | $(168.6) | | $1,845.2 | |
| | | | | | | |
| Twelve Months Ended December 31, 2018 | |
| | 2018 Reported Valued at 2020 Management Rates | | Discontinued Operations and Related Allocation Changes | | 2018 Continuing Operations Valued at 2020 Management Rates | |
Net Sales | | | | | | | |
Global Industrial | | $5,690.3 | | $(1.8) | | $5,688.5 | |
Global Institutional | | 4,255.2 | | - | | 4,255.2 | |
Global Healthcare and Life Sciences | | 915.7 | | - | | 915.7 | |
Upstream Energy | | 2,422.3 | | (2,422.3) | | - | |
Other | | 1,155.3 | | - | | 1,155.3 | |
Subtotal at fixed currency | | 14,438.8 | | (2,424.1) | | 12,014.7 | |
Effect of foreign currency translation | | 229.4 | | (22.0) | | 207.4 | |
Total reported GAAP net sales | | $14,668.2 | | $(2,446.1) | | $12,222.1 | |
Operating Income | | | | | | | |
Global Industrial | | $834.0 | | $(80.3) | | $753.7 | |
Global Institutional | | 905.0 | | (3.5) | | 901.5 | |
Global Healthcare and Life Sciences | | 135.1 | | (10.7) | | 124.4 | |
Upstream Energy | | 172.3 | | (172.3) | �� | - | |
Other | | 174.6 | | (10.6) | | 164.0 | |
Corporate | | (302.7) | | 60.9 | | (241.8) | |
Subtotal at fixed currency | | 1,918.3 | | (216.5) | | 1,701.8 | |
Effect of foreign currency translation | | 28.7 | | (2.2) | | 26.5 | |
Total reported GAAP operating income | | $1,947.0 | | $(218.7) | | $1,728.3 | |